James D. Chambers

The promise of Immuno-oncology: implications for defining the value of cancer treatment

Howard L. Kaufman, Michael B. Atkins, Prasun Subedi et al. · Journal for ImmunoTherapy of Cancer · 2019 · 111 citations · Full text

Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement

Peter J. Neumann, James D. Chambers, Françoise Simon et al. · Health Affairs · 2011 · 103 citations

Drug Policy, Riskbenefit Ratio, Financial Protection +21

The influence of time horizon on results of cost-effectiveness analyses

David D. Kim, Colby Wilkinson, Elle Pope et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2017 · 93 citations

Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss

Neal R. Barshes, James D. Chambers, Joshua T. Cohen et al. · Journal of Vascular Surgery · 2012 · 85 citations

Critical Care Management, Contemporary Management, Limb Reconstruction +10

Listening to Provenge — What a Costly Cancer Treatment Says about Future Medicare Policy

James D. Chambers, Peter J. Neumann · New England Journal of Medicine · 2011 · 66 citations

Health Reform, Future Medicare Policy, Cancer Management +18